Roche Co-Developed Drugs Deliver Early Synergistic Results Without Added Toxicities
This article was originally published in Pharmaceutical Approvals Monthly
ORLANDO, Fla. – Early data from a pioneering study that combines two Roche experimental cancer drugs show their effect may be greater than what might be expected from their individual profiles, with no added toxicities.
You may also be interested in...
FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.